Back-to-back US FDA advisory committee panels for testosterone products have resulted not only in two recommendations against approval, but also spotlighted the difficulties of using such therapies in clinical practice.
The Bone, Reproductive and Urologic Drugs Advisory Committee voted Jan. 9 and Jan. 10 that Clarus Therapeutics Inc.'s Jatenzo...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?